Author: Dino Mustafić

October 2, 2015 Off

FDA: Accelerated approval for Keytruda for patients with advanced (NSCLC) lung cancer

accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)

October 2, 2015 Off

Vectura Group gets €5M upon partner’s work in Europe

By Dino Mustafić

Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.

October 2, 2015 Off

Allergan – Humana Research Partnership

By Dino Mustafić

Allergan plc, has announced a multi-year research collaboration with Humana Inc. to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.

October 2, 2015 Off

Pfizer acquisition of GlaxoSmithKline’s vaccines Nimenrix and Mencevax

By Dino Mustafić

Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.

October 2, 2015 Off

Vernalis Acquires U.S. Rights to Moxatag

By Dino Mustafić

Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).

October 2, 2015 Off

Merck and DNAtrix to evaluate the efficacy and safety of DNX-2401

By Dino Mustafić

Merck, known as MSD outside the United States and Canada, and DNAtrix announced on Thursday that they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.

October 2, 2015 Off

Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program

By Dino Mustafić

Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.

October 2, 2015 Off

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

By Dino Mustafić

Novartis company has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.

October 1, 2015 Off

FDA Advises: Don’t use NATUREAL nor and Ultimate Herbal Slimcap weight loss programes

By Dino Mustafić

The Food and Drug Administration (FDA) is advising consumers not to purchase or use NATUREAL, a product promoted and sold for weight loss.

October 1, 2015 Off

Bayer CropScience: Horticulture Symposium in Puerto Vallarta, Mexico

By Dino Mustafić

Bayer has announced that from September 30th to October first, Bayer CropScience is hosting over 175 industry professionals from over 15 different countries at its Horticulture Symposium in Puerto Vallarta, Mexico.